Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 159-164, January 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leung, S. Y.
Right arrow Articles by Ho, J. C. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leung, S. Y.
Right arrow Articles by Ho, J. C. I.
[Cancer Research 59, 159-164, January 1, 1999]
© 1999 American Association for Cancer Research

Molecular Biology and Genetics

hMLH1 Promoter Methylation and Lack of hMLH1 Expression in Sporadic Gastric Carcinomas with High-Frequency Microsatellite Instability1

Suet Yi Leung2,, 3, Siu Tsan Yuen2, Lap Ping Chung, Kent Man Chu, Annie S. Y. Chan and Joana C. I. Ho

Departments of Pathology [S. Y. L., S. T. Y., L. P. C., A. S. Y. C., J. C. I. H.] and Surgery [K. M. C.], The University of Hong Kong, Queen Mary Hospital, Hong Kong


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Mutation of DNA mismatch repair genes has rarely been documented in sporadic gastric carcinoma with microsatellite instability (MSI). In sporadic colorectal carcinoma, hMLH1 promoter methylation associated with protein loss is found in the majority of high-frequency MSI cases. We investigated a series of 35 sporadic gastric carcinomas stratified into high-frequency MSI (MSI-H), low-frequency MSI (MSI-L) and microsatellite stable (MSS) groups and found that hypermethylation of the CpG island in the hMLH1 promoter region was present in 100% of MSI-H sporadic gastric carcinomas. In 90% of cases, there was an associated complete loss of hMLH1 protein, as detected by immunohistochemistry, and a markedly lowered hMLH1 mRNA level. This loss of hMLH1 protein occurred in the MSI-H invasive tumor but not in the adjacent carcinoma-in situ or dysplastic components that were MSS. The MSI-L and MSS forms of gastric carcinoma all showed predominantly unmethylated hMLH1 promoter, positive hMLH1 protein and high hMLH1 mRNA level. On the other hand, hMSH2 protein was expressed in all of the tumors irrespective of the MSI status. Our results suggest that high-frequency MSI in sporadic gastric cancer is mostly due to epigenetic inactivation of hMLH1 in association with promoter methylation, and the loss of hMLH1 protein is a significant event in the development of invasive tumor.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
MSI4 has been found in 15–39% of sporadic gastric carcinomas worldwide (1, 2, 3, 4, 5, 6, 7, 8, 9) . Although MSI is present in a high proportion of colorectal carcinomas in the young (10 , 11) , the MSI type of gastric carcinomas are mostly seen in the elderly. Gastric carcinomas with a high-frequency of MSI are associated with specific clinico-pathological characteristics including (a) an antral location; (b) intestinal type differentiation; (c) more abundant lymphoid infiltrate; (d) less lymph node metastasis; and (e) better survival rate (4, 5, 6 , 8 , 9) . This clustering suggests that these cases may constitute a group with a common and specific pathway for carcinogenesis. MSI is present in the majority of tumors developing in hereditary nonpolyposis colon cancer syndrome and germline DNA MMR genes mutation can be detected in more than 60% of these individuals (12, 13, 14, 15, 16) . However, the cause of MSI in sporadic tumors is less clear. Somatic mutation in one of the MMR genes has been found in up to 26% of sporadic MSI colorectal carcinomas (17, 18, 19, 20, 21, 22) and 22% of sporadic MSI endometrial carcinomas (23, 24, 25) . Germline MMR gene mutation on the other hand, is mostly limited to young patients among the sporadic colorectal carcinoma cases (10 , 11) .

Immunohistochemical staining has proven to be a useful adjunct in examining the DNA MMR system. Studies on tumors with MSI and germline MMR gene mutations have shown that immunohistochemistry can predict the presence of a defective DNA MMR component. The loss of the corresponding protein is seen in nearly all of the tumors with germline MMR gene mutation, except for the occasional case with missense mutation (21 , 26 , 27) . Interestingly, in a recent study (28) , 90% of sporadic high-frequency MSI colorectal carcinomas were found to have lost the hMLH1 protein.

Aberrant methylation of the promotor has been known to cause transcriptional silencing of some important tumor suppressor genes, such as p16 (29, 30, 31) , E-cadherin (32) , and the von Hippel Lindau (VHL) gene (33) , and this has been implicated in the carcinogenic process in many cancers (see review, Ref. 34 ). Loss of the hMLH1 mRNA or protein was initially found in two colorectal cancer cell lines and in a few sporadic colorectal carcinomas associated with aberrant methylation of the hMLH1 promoter (35) . More recently, promoter methylation associated with loss of the hMLH1 protein was found in some MMR defective colorectal and endometrial cancer cell lines in which mutation in the 4 MMR genes, including hMSH2, hMLH1, hPMS2 and hPMS1, was absent. Treatment of these cell lines with 5-azacytidine restored the expression of hMLH1 protein and MMR capability (36 , 37) . hMLH1 promoter methylation and protein loss were also noted in a high proportion of sporadic MSI colorectal carcinoma samples (36 , 38) . On the other hand, the promoter of hMSH2 was rarely methylated. These data suggest that aberrant methylation of the hMLH1 promoter is potentially a very important mechanism in the deactivation of the MMR system in colorectal carcinoma, but little is known about this process and its role in gastric cancer.

We used monoclonal antibodies to screen for the loss of hMSH2 and hMLH1 proteins in a series of MSI-H, MSI-L and MSS gastric cancers and investigated the underlying mechanisms for the loss of the respective MMR protein.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Tumors.
Thirty-five primary gastric carcinomas were selected from an ongoing study of 130 cases that had been tested for microsatellite instability using at least 6 of 8 loci, including both dinucleotide repeats (Tp53, D18S58, D18S57, D2S123, D5S346) and polyadenine tracts (BAT26, BAT40, BAT-RII). The results from a major proportion of these cases have been reported previously (9) . All of the 11 MSI-H, all of the 5 MSI-L, and 19 randomly selected MSS gastric carcinomas among the 130 cases were evaluated for the relationship of MSI to MMR protein expression, promoter methylation, and MMR gene mRNA level. Cases were referred to as MSI-H if there were more than 40% unstable loci, MSI-L if less than 40% unstable loci, and MSS if no unstable loci (9 , 39 , 40) . The methods used were as described previously (9) . The microsatellite loci alterations in the MSI cases are listed in Table 1Citation .


View this table:
[in this window]
[in a new window]
  		Table 1 Clinicopathological features and microsatellite loci altered in 5 MSI-L and 11 MSI-H gastric adenocarcinomas

 
Immunohistochemistry.
Immunostaining for hMSH2 and hMLH1 were performed in all of the cases using the standard streptavidin-biotin-peroxidase complex method as described previously (27) . Six-µm thick sections of 10% neutral buffered formalin-fixed, paraffin-embedded tumor tissue were incubated for 1 h at 37°C with monoclonal antibodies against the NH2-terminal fragment (clone GB12; dilution 1:20; Oncogene Research Products, Cambridge, MA) and COOH-terminal fragment of hMSH2 (clone FE11; dilution 1:200; Oncogene Research Products, Cambridge, MA). For hMLH1, sections were incubated at 37°C for 1 h using a monoclonal antibody (clone G168–15; dilution 1:10; PharMingen, San Diego, CA). Microwave pretreatment at 95°C for 30 min in citrate buffer (pH 6.0) was performed after deparaffinization. For negative control, the primary antibodies were replaced with mouse IgG (Dakopatts, Glostrup, Denmark). The staining results were examined and graded without knowledge of the MSI status. Normal tissues were taken as internal positive control, and cases were graded only if there was positive nuclear staining in the regenerative mucosal cells and lymphoid cells in the germinal center. The stains were graded: (a) negative when there was complete absence of staining in the tumor cell nuclei; and (b) positive when there was positive staining in the tumor cell nuclei.

hMLH1 Promoter Methylation.
The methods used were similar to those of Kane et al. (35) with some modification. pBluescript II KS phagemid DNA (4.4 pg) were added to 250 ng of genomic DNA in a 30-µl volume of restriction endonuclease buffer. The pBluescript II DNA serve as internal control for cleavage by HpaII and MspI because the CpG sites in the recognition sequences of these enzymes are not cytosine-methylated and can be cleaved to completion by both enzymes. The reactions contained either no enzyme, 25 units of HpaII, or 20 units of MspI for 12 h at 37°C.

The cleavage of the hMLH1 promoter region was analyzed by a pair of primers similar to Kane et al. (35) , amplifying nucleotides -670 to -67 of hMLH1. Four HpaII sites in positions -567, -527, -347, and -341 were included in this region. Twenty ng of each digest was analyzed by PCR in 25-µl reactions containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1 mM MgCl2, 0.2 mM dNTP, 0.5 units of Taq, and 0.1 µM each primers. PCR was performed for one cycle of 95°C for 5 min, followed by 35 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 30 s, followed by one cycle of 72°C for 7 min. The PCR products were analyzed by agarose gel electrophoresis. Analysis of DNA methylation was performed in the absence of knowledge of the hMLH1 expression status in all of the experiments.

Cleavage of the control pBluescript II DNA was analyzed as above with the M13 universal primers, flanking a 209-bp region with two HpaII sites.

hMLH1 Expression by RT-PCR.
Total RNA was extracted from frozen blocks using the standard guanidium thiocyanate method. Guided by the frozen sections, the tumor areas were dissected out from the blocks for RNA extraction. The RNA was then subjected to electrophoresis on 1% agarose gel to ensure the quality. For reverse transcription, cDNA was generated in a 20 µl reaction in the presence of 2 µg total RNA, 100 ng Oligo-dT, 10 mM DTT, 500 µM dNTP, 5 units reverse transcriptase, 10 units of RNase inhibitor and buffer containing 50 mM Tris-HCl (pH8.3), 75 mM KCl and 3 mM MgCl2, which was supplied by the manufacturer (Life Technologies, BRL). The reaction was carried out at 42°C for 1 h and then 70°C for 10 min.

The normalization of cDNA was performed using the method of competitive RT-PCR with a pair of primers for human ß-actin (forward primer, 5'-ACTCTTCCAGCCTTCCTTCC-3'; reverse primer, 5'-CGTCATACTCCTGCTTGCTG-3') and with addition of 31.25 fg of internal ß-actin competitor DNA as described previously (41) . The ß-actin competitor was constructed by false priming salmon sperm DNA with the same ß-actin primers followed by cloning of the PCR product and sequencing to confirm the presence of both the forward and reverse ß-actin primer binding sites. The cycle number and amount of internal ß-actin competitor DNA were chosen to ensure that the amplification was not in the plateau phase. Serial dilutions of the tumor cDNA were added to the PCR reaction. The PCR reaction was carried out in a 25-µl reaction containing 0.4 µM of each forward and reverse ß-actin primer, 0.2 mM dNTP, 2.5 mM MgCl2, 1 unit Taq DNA polymerase, buffer containing 50 mM Tris-HCl (pH 8.3), 50 mM KCl supplied by the manufacturer, and 5 µl cDNA. Twenty-five cycles of 45 s at 94°C, 45 s at 60°C, and 45 s at 72°C were carried out in an automatic thermal cycler. The products were visualized by gel electrophoresis and ethidium bromide staining. The cDNA dilution was chosen in which the amount of target and competitor amplicons were similar in intensity as determined by the GDS8000 Complete Gel Documentation and Analysis System (UV Products, Cambridge, United Kingdom) based on the volume intensity of the bands. After optimal tumor cDNA dilution was selected, the reaction was duplicated to ensure reproducible results.

The normalized cDNA was subjected to PCR using a pair of primers flanking nucleotides 471-1104 of the hMLH1 cDNA (forward primer, 5'-CAACATAGCCACGAGGAGAA; reverse primer, 5'-CGAGGTCAGACTTGTTGTGGA). The PCR condition was similar to that described above with minor modifications. Thirty cycles of amplification were performed using 60°C annealing temperature and 3 mM MgCl2, and the resultant band was visualized by gel electrophoresis and ethidium bromide staining. The cycle number was chosen to ensure that the amplification was not in the plateau phase. The band intensity was determined by the Gel Documentation System with reference to a known amount of pBluescript/MSP1 DNA marker. The RT-PCR analysis was performed without knowledge of the hMLH1 promoter methylation and protein expression status.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
The results of MMR protein expression, hMLH1 promoter methylation, and hMLH1 gene expression are summarized in Table 2Citation .


View this table:
[in this window]
[in a new window]
  		Table 2 Relationship of MSI, hMLH1 promoter methylation, hMLH1 protein, and mRNA expression in 35 gastric adenocarcinomas

 
Immunohistochemistry.
Both hMSH2 and hMLH1 staining of the non-neoplastic tissue were consistent with those reported previously (21 , 26 , 42 , 43) , with strong positive nuclear staining of cells in the proliferating compartments. The regenerative mucosal epithelial cells in the foveolar neck and lymphoid cells in germinal center were strongly positive. Foci of intestinal metaplasia were strongly positive, whereas the staining was weak or absent in the mature superficial mucosal cells (Fig. 1a)Citation . Fibroblasts and endothelial cells were variably positive for the proteins.



View larger version (133K):
[in this window]
[in a new window]
  		Fig. 1. Immunohistochemistry of hMLH1 in gastric adenocarcinoma. a, gastric mucosa with intestinal metaplasia positive for the protein. x165. b, a MSI-H gastric carcinoma with promoter methylation and complete loss of hMLH1 protein. The adjacent regenerative mucosal cells and lymphoid cells are positive for the protein. x125. c, a MSI-H case with preserved hMLH1 expression in the dysplastic and carcinoma in situ areas (left field) but with complete loss of the protein in the invasive part (right lower field). x50. d, high power of the invasive tumor in c. Scattered lymphoid cells are positive whereas all of the tumor nuclei are negative. x125. e and f, high power of the carcinoma in situ foci in c with positive hMLH1 protein. x200. g, a MSI-L case with positive staining for hMLH1. x165. h, a MSI-L case with positive staining for hMSH2. x165.

 
In the gastric adenocarcinomas, complete loss of the hMLH1 protein was noted in 10 of 11 MSI-H cases (Fig. 1b)Citation . For all of the cases showing loss of the hMLH1 protein, there were positive fibroblasts, lymphoid cells or nonneoplastic mucosal cells admixed with and adjacent to the tumor. In 1 of the 10 cases, areas of mild dysplasia were noted, and these cells were positive for the protein. In another case, extensive areas of intestinal metaplasia, dysplasia, and carcinoma in situ were noted at the tumor edge, where there was a transition to invasive carcinoma. It is notable that the hMLH1 protein was still expressed in the metaplasia, dysplasia, and carcinomain situ but was completely absent in the invasive part of this tumor (Fig. 1, c–f)Citation . Microsatellite analysis of DNA extracted from the dysplastic and carcinoma in situ components in this case showed microsatellite stable phenotype; thus, the onset of MSI correlated with the loss of the hMLH1 protein. The remaining MSI-H case had positive protein expression in the tumor cell nuclei, but the intensity was weaker than the nonneoplastic regenerating mucosal cells. All of the 5 MSI-L and the 19 MSS cases showed expression of the hMLH1 proteins in the tumor cells (Fig. 1g)Citation . All of the 35 tumors, irrespective of the MSI status, showed positive nuclear staining for the two hMSH2 antibodies (Fig. 1h)Citation .

hMLH1 Promoter Methylation Analysis.
All of the 11 MSI-H cases showed the hMLH1 promoter region to be highly resistant to HpaII digestion but sensitive to digestion by MspI, consistent with methylation of all of the four HpaII sites (Fig. 2)Citation . Ten of these 11 cases had complete loss of the hMLH1 protein, and the remaining case gave a weak positive staining.



View larger version (33K):
[in this window]
[in a new window]
  		Fig. 2. Analysis of gastric adenocarcinomas for hMLH1 promoter methylation. A, amplification of the hMLH1 promoter region before and after digestion with the specific restriction endonucleases. B, amplification of unmethylated internal control pBluescript DNA before and after digestion with the indicated restriction endonucleases. U, undigested; M, digested with MspI; H, digested with HpaII; B, pBluescript/MspI DNA marker. The MSI-H cases have predominantly methylated hMLH1 promoter, whereas the MSI-L and MSS cases have unmethylated genes sensitive to HpaII digestion. Cases T1-T3 do not express hMLH1 protein and have a low hMLH1 mRNA level.

 
The DNA isolated from all of the 5 MSI-L and 19 MSS cases were sensitive to digestion by both HpaII and MspI (Fig. 2)Citation . In four of the MSS cases, a small amount of HpaII-resistant DNA was seen despite replenishment with excess restriction endonuclease. This suggests the presence of a small population of tumor cells with hMLH1 promoter methylation or possibly that one allele of the hMLH1 was methylated. In all of the MSI-L and MSS cases, the MLH1 protein was expressed in the tumor. In all cases, the unmethylated internal control DNA was completely digested by HpaII and MspI.

The association of MSI-H with hMLH1 promoter methylation and hMLH1 protein loss was statistically highly significant using the Fisher’s exact test (P < 0.00001).

hMLH1 mRNA Expression by RT-PCR.
The mRNA expression in the 11 MSI-H, 5 MSI-L and 14 MSS cases was assessed by RT-PCR; representative results are shown in Fig. 3Citation . The mean level of hMLH1 mRNA in cases with MSI-H and hMLH1 promoter methylation was significantly lower than the MSI-L (P = 0.009) and MSS cases (P = 0.0001) using the Mann-Whitney U test (Fig. 4Citation and Table 2Citation ). The hMLH1 mRNA level was also significantly lower in the tumors with no hMLH1 protein (P < 0.0001).



View larger version (37K):
[in this window]
[in a new window]
  		Fig. 3. hMLH1 mRNA expression by RT-PCR. The tumor cDNAs are normalized by competitive ß-actin RT-PCR. Upper panel: the upper band is amplified from a known constant amount of competitor DNA by the same ß-actin primers. The lower bands correspond to the ß-actin cDNA amplified from the tumor. The concentration of the tumor cDNA is adjusted to give a band of similar intensity to the competitor. Lower panel: hMLH1 expression in the normalized tumor samples. Lanes 1–7 are from MSI-H cases, Lane 10 from a MSI-L case, Lanes 8, 9, and 11–14 from MSS cases. N, negative control with internal competitor and without tumor cDNA.

 


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 4. Box-and-whisker plot of the expression of hMLH1 gene in MSI-H, MSI-L, and MSS gastric carcinomas. Line inside box, the median; upper and lower limits of box, hinges—75th and 25th percentiles, respectively; vertical bars above and below the box, the upper and lower quartiles, respectively.

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Our data document the importance of aberrant methylation of the hMLH1 promoter in causing MSI-H in sporadic gastric cancer. Aberrant hMLH1 promoter methylation was present in 100% of the MSI-H cases. This is associated with a lowered level of mRNA and a total absence of the hMLH1 protein in more than 90% of cases, supporting the former as the cause of transcriptional silencing of this gene. The remaining weak mRNA expression in the MSI-H, hMLH1 promoter methylated, and protein-negative cases is most probably derived from the admixed normal cells within the tumor. Although we cannot exclude the possibility of mutation being the underlying cause for the loss of hMLH1 protein and MSI phenotype in some of these cases with promoter methylation, this possibility even if it exists, is estimated to account for only a small proportion of cases. Somatic mutation in one of the MMR genes has been detected in at most 26% of sporadic MSI cancers in various organs (17, 18, 19, 20, 21, 22, 23, 24, 25) . In sporadic gastric cancer, data on MMR gene mutation is scarce, and thus far only five somatic mutations in the MMR genes have been reported (44 , 45) . On the other hand, methylation of the CpG island in the promoter is known to cause transcriptional silencing of many tumor suppressor genes, and de-methylation of the hMLH1 promoter has been shown to restore the hMLH1 protein expression and MMR capacity in colorectal cancer cell lines (36 , 37) .

Our findings are that the loss of the hMLH1 protein is a significant event operating in tumor progression rather than initiation in gastric cancer. The preservation of the hMLH1 protein in intestinal metaplasia, dysplasia, and carcinoma in situ phases, and its complete absence in the whole invasive tumor associated with onset of MSI suggests that there is rapid clonal expansion and invasive tumor formation once the hMLH1 protein is lost. This may be achieved by accelerated mutation of important growth regulatory genes such as transforming growth factor ß type II receptor or Bax. An analogy can be drawn with the colorectal adenoma-carcinoma sequence where MSI has been found to play a role in tumor progression rather than in the initiation phase. MSI is only rarely found in adenomas and there is a significant increase of MSI in benign adenoma with areas of malignancy and in cancer (46, 47, 48, 49, 50) .

Interestingly, none of the MSI-L gastric carcinomas showed loss of either hMSH2 or hMLH1 proteins, a result similar to the MSS cases. This supports the previous observation that the MSI-H cases had specific clinicopathological features (4, 5, 6 , 8 , 9) , and the mechanism for the MMR defect is probably different from the MSI-L cases. Similarly, MSI-L colorectal carcinomas were indistinguishable from the MSS counterparts in clinicopathological features, and they had normal hMSH2 and hMLH1 protein expression (28) . It is possible that another component of the MMR system may be inactivated by yet unknown mechanisms in the MSI-L cancers.

A small amount of HpaII-resistant DNA was detected in four MSS gastric carcinomas with positive hMLH1 protein expression. Similar observations were noted in a few cases of MSS colorectal carcinomas (36 , 38) and MSS endometrial carcinomas (51) . These cases may represent the presence of a small population of tumor cells with methylation or hemimethylation. Also, one MSI-H gastric carcinoma showed prominent promoter methylation but still expressed the hMLH1 protein, and a similar case of MSI colorectal carcinoma was noted previously (36) . It is likely that methylation of the CpG sites analyzed is important but not sufficient for gene inactivation. This is not surprising because the density of CpG island methylation in the 5' regulatory region in general correlates with the degree of transcriptional repression in a gene. Further study to map the methylation status of CpG sites in a larger region and to correlate with protein expression may help to resolve these issues.

The cause of the deranged methylation remains poorly understood. Taken together with data from previous studies in which methylation of a variety of endogenous genes and exogenous retroviral gene sequences were seen more frequently in MMR-deficient colorectal cancers when compared with their MMR proficient counterparts (52 , 53) , MMR deficiency in sporadic gastric cancer may in fact be the result of a deranged methylation state in the individual. This aberrant methylation can cause cancer by inactivation of the hMLH1 promoter and lead to the mutator phenotype. Similarly, this mechanism can also inactivate other important growth regulatory genes. Moreover, this aberrant methylation status appears to be an actively maintained process in MSI-cancer cell lines; the hMLH1 expression can be turned on and off with 5-azacytidine exposure and washout (37) . Further study to define the mechanism underlying this methylation process will be crucial in our understanding of this type of epigenetic event in carcinogenesis.


   ACKNOWLEDGMENTS
 
We thank Ivan S. H. Ho and Murray C. K. Chu for excellent technical assistance and Dr. Robert J. Collins for critical reading of the article.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work is supported by the Michael and Betty Kadoorie Foundation Cancer Research Genetics Fund. Back

2 Both authors have contributed equally to this work. Back

3 To whom requests for reprints should be addressed, at Department of Pathology, Queen Mary Hospital, Pokfulam Road, Hong Kong. Phone: 852-28554401; Fax: 852-28725197; Email: suetyi{at}hkucc.hku.hk Back

4 The abbreviations used are: MSI, microsatellite instability; MSI-H, high-frequency MSI; MSI-L, low-frequency MSI; MSS, microsatellite stable; MMR, mismatch repair; RT-PCR, reverse transcription-PCR. Back

Received 9/11/98. Accepted 10/30/98.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Han H. J., Yanagisawa A., Kato Y., Park J. G., Nakamura Y. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res., 53: 5087-5089, 1993.[Abstract/Free Full Text]
  2. Strickler J. G., Zheng J., Shu Q., Burgart L. J., Alberts S. R., Shibata D. p53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res., 54: 4750-4755, 1994.[Abstract/Free Full Text]
  3. Chong J. M., Fukayama M., Hayashi Y., Takizawa T., Koike M., Konishi M., Kikuchi Yanoshita R., Miyaki M. Microsatellite instability in the progression of gastric carcinoma. Cancer Res., 54: 4595-4597, 1994.[Abstract/Free Full Text]
  4. dos Santos N. R., Seruca R., Constancia M., Seixas M., Sobrinho Simoes M. Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology, 110: 38-44, 1996.[Medline]
  5. Chung Y. J., Song J. M., Lee J. Y., Jung Y. T., Seo E. J., Choi S. W., Rhyu M. G. Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population. Cancer Res., 56: 4662-4665, 1996.[Abstract/Free Full Text]
  6. Ottini L., Palli D., Falchetti M., D’Amico C., Amorosi A., Saieva C., Calzolari A., Cimoli F., Tatarelli C., Marchis L. D., Masala G., Mariani-Costantini R., Cama A. Microsatellite instability in gastric cancer is associated with tumor location and family history in a high-risk population from Tuscany. Cancer Res., 57: 4523-4529, 1997.[Abstract/Free Full Text]
  7. Hayden J. D., Cawkwell L., Quirke P., Dixon M. F., Goldstone A. R., Sue-Ling H., Johnston D., Martin I. G. Prognostic significance of microsatellite instability in patients with gastric carcinoma. Eur. J. Cancer, 33: 2342-2346, 1997.
  8. Wu M. S., Lee C. W., Shun C. T., Wang H. P., Lee W. J., Sheu J. C., Lin J. T. Clinicopathologial significance of altered loci of replication error and microsatellite instability-associated mutations in gastric cancer. Cancer Res., 58: 1494-1497, 1998.[Abstract/Free Full Text]
  9. Leung, S. Y., Yuen, S. T., Chung, L. P., Chu, K. M., Wong, M. P., Branicki, F. J., and Ho, J. C. I. Microsatellite instability, Epstein-Barr virus, mutation of type II transforming growth factor ß receptor and Bax in gastric carcinomas in Hong Kong Chinese. Br. J. Cancer, in press, 1998.
  10. Liu B., Farrington S. M., Petersen G. M., Hamilton S. R., Parsons R., Papadopoulos N., Fujiwara T., Jen J., Kinzler K. W., Wyllie A. H., Vogelstein B., Dunlop M. G. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat. Med., 1: 348-352, 1995.[Medline]
  11. Yuen S. T., Chan T. L., Leung S. Y., Ho J. W. C., Kwan K., Chung L. P. Microsatellite instability and mismatch repair gene mutation in colorectal cancer patients in Hong Kong. Proc. Am. Assoc. Cancer Res., 39: 474 1998.
  12. Fishel R., Lescoe M. K., Rao M. R., Copeland N. G., Jenkins N. A., Garber J., Kane M., Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell, 75: 1027-1038, 1993.[Medline]
  13. Liu B., Parsons R. E., Hamilton S. R., Petersen G. M., Lynch H. T., Watson P., Markowitz S., Willson J. K., Green J., de la Chapelle A., Kinzler K. W., Vogelstein B. hMSH2 mutations in hereditary nonpolyposis colorectal cancer kindreds. Cancer Res., 54: 4590-4594, 1994.[Abstract/Free Full Text]
  14. Papadopoulos N., Nicolaides N. C., Wei Y. F., Ruben S. M., Carter K. C., Rosen C., Haseltine W. A., Fleischmann R. D., Fraser C. M., Adams M. D., Venter J. C., Hamilton S. R., Petersen G. M., Watson P., Lynch H. T., Peltomaki P., Mecklin J. P., de la Chapelle A., Kinzler K. W., Vogelstein B. Mutation of a mutL homolog in hereditary colon cancer. Science (Washington DC), 263: 1625-1629, 1994.[Abstract/Free Full Text]
  15. Nicolaides N. C., Papadopoulos N., Liu B., Wei Y. F., Carter K. C., Ruben S. M., Rosen C. A., Haseltine W. A., Fleischmann R. D., Fraser C. M., Adams M. D., Venter J. C., Dunlop M. G., Hamilton S. R., Petersen G. M., de la Chapelle A., Vogelstein B., Kinzler K. W. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature (Lond.), 371: 75-80, 1994.[Medline]
  16. Bronner C. E., Baker S. M., Morrison P. T., Warren G., Smith L. G., Lescoe M. K., Kane M., Earabino C., Lipford J., Lindblom A., Tannergard P., Bollag R. J., Godwin A. R., Ward D. C., Nordenskjold M., Fishel R., Kolodner R., Liskay R. M. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature (Lond.), 368: 258-261, 1994.[Medline]
  17. Borresen A. L., Lothe R. A., Meling G. I., Lystad S., Morrison P., Lipford J., Kane M. F., Rognum T. O., Kolodner R. D. Somatic mutations in the hMSH2 gene in microsatellite unstable colorectal carcinomas. Hum. Mol. Genet., 4: 2065-2072, 1995.[Abstract/Free Full Text]
  18. Liu B., Nicolaides N. C., Markowitz S., Willson J. K., Parsons R. E., Jen J., Papadopoulos N., Peltomaki P., de la Chapelle A., Hamilton S. R., Kinzler K. W., Vogelstein B. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat. Genet., 9: 48-55, 1995.[Medline]
  19. Moslein G., Tester D. J., Lindor N. M., Honchel R., Cunningham J. M., French A., Halling K. C., Schwab M., Goretzki P., Thibodeau S. N. Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum. Mol. Genet., 5: 1245-1252, 1996.[Abstract/Free Full Text]
  20. Bubb V. J., Curtis L. J., Cunningham C., Dunlop M. G., Carothers A. D., Morris R., White S., Bird C. C., Wyllie A. H. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene, 12: 2641-2649, 1996.[Medline]
  21. Thibodeau S. N., French A. J., Roche P. C., Cunningham J. M., Tester D. J., Lindor N. M., Moslein G., Baker S. M., Liskay R. M., Burgart L. J., Honchel R., Halling K. C. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res., 56: 4836-4840, 1996.[Abstract/Free Full Text]
  22. Wu Y., Nystrom Lahti M., Osinga J., Looman M. W., Peltomaki P., Aaltonen L., de la Chapelle A., Hofstra R. M., Buys C. H. MSH2 and MLH1 mutations in sporadic replication error-positive colorectal carcinoma as assessed by two-dimensional DNA electrophoresis. Genes Chromosomes Cancer, 18: 269-278, 1997.[Medline]
  23. Katabuchi H., van Rees B., Lambers A. R., Ronnett B. M., Blazes M. S., Leach F., Cho K. R., Hedrick L. Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res., 55: 5556-5560, 1995.[Abstract/Free Full Text]
  24. Kobayashi K., Matsushima M., Koi S., Saito H., Sagae S., Kudo R., Nakamura Y. Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic endometrial carcinomas with microsatellite instability. Jpn. J. Cancer Res., 87: 141-145, 1996.[Medline]
  25. Kowalski L. D., Mutch D. G., Herzog T. J., Rader J. S., Goodfellow P. J. Mutational analysis of MLH1 and MSH2 in 25 prospectively acquired RER+ endometrial cancers. Genes Chromosomes Cancer, 18: 219-227, 1997.[Medline]
  26. Leach F. S., Polyak K., Burrell M., Johnson K. A., Hill D., Dunlop M. G., Wyllie A. H., Peltomaki P., de la Chapelle A., Hamilton S. R., Kinzler K. W., Vogelstein B. Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. Cancer Res., 56: 235-240, 1996.[Abstract/Free Full Text]
  27. Leung S. Y., Chan T. L., Chung L. P., Chan A. S. Y., Fan Y. W., Hung K. N., Kwong W. K., Ho J. W. C., Yuen S. T. Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. Am. J. Pathol., 153: 1181-1188, 1998.[Abstract/Free Full Text]
  28. Thibodeau S. N., French A. J., Cunningham J. M., Tester D., Burgart L. J., Roche P. C., McDonnell S. K., Schaid D. J., Vockley C. W., Michels V. V., Farr G. H., O’Connell M. J. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res., 58: 1713-1718, 1998.[Abstract/Free Full Text]
  29. Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S., Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.[Medline]
  30. Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J. P., Davidson N. E., Sidransky D., Baylin S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.[Abstract/Free Full Text]
  31. Gonzalez-Zulueta M., Bender C. M., Yang A. S., Nguyen T., Beart R. W., Van Tornout J. M., Jones P. A. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531-4535, 1995.[Abstract/Free Full Text]
  32. Graff J. R., Herman J. G., Lapidus R. G., Chopra H., Xu R., Jarrard D. F., Isaacs W. B., Pitha P. M., Davidson N. E., Baylin S. B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res., 55: 5195-5199, 1995.[Abstract/Free Full Text]
  33. Herman J. G., Latif F., Weng Y., Lerman M. I., Zbar B., Liu S., Samid D., Duan D. S., Gnarra J. R., Linehan W. M., Baylin S. B. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA, 91: 9700-9704, 1994.[Abstract/Free Full Text]
  34. Baylin S. B., Herman J. G., Graff J. R., Vertino P. M., Issa J. P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res., 72: 141-196, 1998.[Medline]
  35. Kane M. F., Loda M., Gaida G. M., Lipman J., Mishra R., Goldman H., Jessup J., Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res., 57: 808-811, 1997.[Abstract/Free Full Text]
  36. Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. J., Markowitz S., Willson J. V., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Vogelstein B., Kunkel T. A., Baylin S. B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870-6875, 1998.[Abstract/Free Full Text]
  37. Veigl M. L., Kasturi L., Olechnowicz J., Ma A. H., Lutterbaugh J. D., Periyasamy S., Li G. M., Drummond J., Modrich P. L., Sedwick W. D., Markowitz S. D. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc. Natl. Acad. Sci. USA, 95: 8698-8702, 1998.[Abstract/Free Full Text]
  38. Cunningham J. M., Christensen E. R., Tester D. J., Kim C. Y., Roche P. C., Burgart L. J., Thibodeau S. N. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res., 58: 3455-3460, 1998.[Abstract/Free Full Text]
  39. Dietmaier W., Wallinger S., Bocker T., Kullmann F., Fishel R., Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res., 57: 4749-4756, 1997.[Abstract/Free Full Text]
  40. Bocker T., Diermann J., Friedl W., Gebert J., Holinski Feder E., Karner H-J., von Knebel Doeberitz M., Koelble K., Moeslein G., Schackert H. K., Wirtz H. C., Fishel R., Ruschoff J. Microsatellite instability analysis: a multicenter study for reliability and quality control. Cancer Res., 57: 4739-4743, 1997.[Abstract/Free Full Text]
  41. Cheung M. N., Wong M. P., Yuen S. T., Leung S. Y., Chung L. P. Tissue-specific expression pattern of vascular endothelial growth factor isoforms changes during malignant transformation. Hum. Pathol., 29: 910-914, 1998.[Medline]
  42. Fink D., Nebel S., Aebi S., Zheng H., Kim H. K., Christen R. D., Howell S. B. Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues. Br. J. Cancer, 76: 890-893, 1997.[Medline]
  43. Wilson T. M., Ewel A., Duguid J. R., Eble J. N., Lescoe M. K., Fishel R., Kelley M. Differential cellular expression of the human MSH2 repair enzyme in small and large intestine. Cancer Res., 55: 5146-5150, 1995.[Abstract/Free Full Text]
  44. Semba S., Yokozaki H., Yasui W., Tahara E. Frequent microsatellite instability and loss of heterozygosity in the region including BRCA1 (17q21) in young patients with gastric cancer. Int. J. Oncol., 12: 1245-1251, 1998.[Medline]
  45. Hatta Y., Wada M., Takeuchi S., Tasaka T., Lee E., Lee Y. Y., Kim B. K., Bang Y. J., Lee S., Yamada Y., Tomonaga M., Wilczynski S. P., Said J. W., Koeffler H. P. Mutational analysis of the hMSH2 gene in a wide variety of tumors. Int. J. Oncol., 11: 465-469, 1997.
  46. Samowitz W. S., Slattery M. L. Transforming growth factor-ß receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas. Am. J. Pathol., 151: 33-35, 1997.[Abstract]
  47. Samowitz W. S., Slattery M. L. Microsatellite instability in colorectal adenomas. Gastroenterology, 112: 1515-1519, 1997.[Medline]
  48. Young J., Searle J., Buttenshaw R., Thomas L., Ward M., Chenevix T., Leggett B. An Alu VpA marker on chromosome I demonstrates that replication errors manifest at the adenoma-carcinoma transition in sporadic colorectal tumors. Genes Chromosomes Cancer, 12: 251-254, 1995.[Medline]
  49. Jacoby R. F., Marshall D. J., Kailas S., Schlack S., Harms B., Love R. Genetic instability associated with adenoma to carcinoma progression in hereditary nonpolyposis colon cancer. Gastroenterology, 109: 73-82, 1995.[Medline]
  50. Young J., Leggett B., Gustafson C., Ward M., Searle J., Thomas L., Buttenshaw R., Chenevix Trench G. Genomic instability occurs in colorectal carcinomas but not in adenomas. Hum. Mutat., 2: 351-354, 1993.[Medline]
  51. Esteller M., Levine R., Baylin S. B., Hendrick Ellenson L, Herman J. G. hMLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Proc. Am. Assoc. Cancer Res., 39: 538 1998.
  52. Ahuja N., Mohan A. L., Li Q., Stolker J. M., Herman J. G., Hamilton S. R., Baylin S. B., Issa J. P. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res., 57: 3370-3374, 1997.[Abstract/Free Full Text]
  53. Lengauer C., Kinzler K. W., Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. Proc. Natl. Acad. Sci. USA, 94: 2545-2550, 1997.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
A. Tsirigos and I. Rigoutsos
Human and mouse introns are linked to the same processes and functions through each genome's most frequent non-conserved motifs
Nucleic Acids Res., June 1, 2008; 36(10): 3484 - 3493.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Suehiro, C. W. Wong, L. R. Chirieac, Y. Kondo, L. Shen, C. R. Webb, Y. W. Chan, A. S.Y. Chan, T. L. Chan, T.-T. Wu, et al.
Epigenetic-Genetic Interactions in the APC/WNT, RAS/RAF, and P53 Pathways in Colorectal Carcinoma
Clin. Cancer Res., May 1, 2008; 14(9): 2560 - 2569.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
A Gylling, W M Abdel-Rahman, M Juhola, K Nuorva, E Hautala, H J Jarvinen, J-P Mecklin, M Aarnio, and P Peltomaki
Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study
Gut, July 1, 2007; 56(7): 926 - 933.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
C. Tzao, G.-H. Sun, H.-J. Tung, H.-S. Hsu, W.-H. Hsu, Y.-C. Wang, Y.-L. Cheng, and S.-C. Lee
Reduced Acetylated Histone H4 is Associated With Promoter Methylation of the Fragile Histidine Triad Gene in Resected Esophageal Squamous Cell Carcinoma
Ann. Thorac. Surg., August 1, 2006; 82(2): 396 - 401.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
M. R. Hussein, A. K. Haemel, D. M. Albert, and G. S. Wood
Microsatellite Instability and Alterations of Mismatch Repair Protein Expression in Choroidal Melanomas
Arch Ophthalmol, December 1, 2005; 123(12): 1705 - 1711.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
C. Tzao, H.-S. Hsu, G.-H. Sun, H.-L. Lai, Y.-C. Wang, H.-J. Tung, C.-P. Yu, Y.-L. Cheng, and S.-C. Lee
Promoter methylation of the hMLH1 gene and protein expression of human mutL homolog 1 and human mutS homolog 2 in resected esophageal squamous cell carcinoma
J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1371 - 1371.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. P. Giacomini, S. Y. Leung, X. Chen, S. T. Yuen, Y. H. Kim, E. Bair, and J. R. Pollack
A Gene Expression Signature of Genetic Instability in Colon Cancer
Cancer Res., October 15, 2005; 65(20): 9200 - 9205.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H.-S. Hsu, C.-K. Wen, Y.-A. Tang, R.-K. Lin, W.-Y. Li, W.-H. Hsu, and Y.-C. Wang
Promoter Hypermethylation Is the Predominant Mechanism in hMLH1 and hMSH2 Deregulation and Is a Poor Prognostic Factor in Nonsmoking Lung Cancer
Clin. Cancer Res., August 1, 2005; 11(15): 5410 - 5416.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Y. Yuasa, H. Nagasaki, Y. Akiyama, H. Sakai, T. Nakajima, Y. Ohkura, T. Takizawa, M. Koike, M. Tani, T. Iwai, et al.
Relationship between CDX2 gene methylation and dietary factors in gastric cancer patients
Carcinogenesis, January 1, 2005; 26(1): 193 - 200.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
K. W. Choy, C. P. Pang, D. S. P. Fan, T. C. Lee, J. H. Wang, D. H. Abramson, K. W. Lo, K. F. To, C. B. O. Yu, K. L. Beaverson, et al.
Microsatellite Instability and MLH1 Promoter Methylation in Human Retinoblastoma
Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3404 - 3409.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Y. Akiyama, C. Maesawa, S. Ogasawara, M. Terashima, and T. Masuda
Cell-Type-Specific Repression of the Maspin Gene Is Disrupted Frequently by Demethylation at the Promoter Region in Gastric Intestinal Metaplasia and Cancer Cells
Am. J. Pathol., November 1, 2003; 163(5): 1911 - 1919.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Colombino, A. Cossu, A. Arba, A. Manca, A. Curci, A. Avallone, G. Comella, G. Botti, F. Scintu, M. Amoruso, et al.
Microsatellite instability and mutation analysis among southern Italian patients with colorectal carcinoma: detection of different alterations accounting for MLH1 and MSH2 inactivation in familial cases
Ann. Onc., October 1, 2003; 14(10): 1530 - 1536.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. P.A. Ebert, J. Yu, J. Hoffmann, A. Rocco, C. Rocken, S. Kahmann, O. Muller, M. Korc, J. J. Sung, and P. Malfertheiner
Loss of Beta-Catenin Expression in Metastatic Gastric Cancer
J. Clin. Oncol., May 1, 2003; 21(9): 1708 - 1714.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Peltomaki
Role of DNA Mismatch Repair Defects in the Pathogenesis of Human Cancer
J. Clin. Oncol., March 15, 2003; 21(6): 1174 - 1179.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
M M Walker
Is intestinal metaplasia of the stomach reversible?
Gut, January 1, 2003; 52(1): 1 - 4.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Kaneda, M. Kaminishi, K. Yanagihara, T. Sugimura, and T. Ushijima
Identification of Silencing of Nine Genes in Human Gastric Cancers
Cancer Res., November 15, 2002; 62(22): 6645 - 6650.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Colombino, A. Cossu, A. Manca, M. F. Dedola, M. Giordano, F. Scintu, A. Curci, A. Avallone, G. Comella, M. Amoruso, et al.
Prevalence and prognostic role of microsatellite instability in patients with rectal carcinoma
Ann. Onc., September 1, 2002; 13(9): 1447 - 1453.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T.-L. Lee, W. K. Leung, M. W. Y. Chan, E. K. W. Ng, J. H. M. Tong, K.-W. Lo, S. C. S. Chung, J. J. Y. Sung, and K.-F. To
Detection of Gene Promoter Hypermethylation in the Tumor and Serum of Patients with Gastric Carcinoma
Clin. Cancer Res., June 1, 2002; 8(6): 1761 - 1766.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
M. R. A.-E. Hussein and G. S. Wood
Molecular Aspects of Melanocytic Dysplastic Nevi
J. Mol. Diagn., May 1, 2002; 4(2): 71 - 80.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Duval and R. Hamelin
Mutations at Coding Repeat Sequences in Mismatch Repair-deficient Human Cancers: Toward a New Concept of Target Genes for Instability
Cancer Res., May 1, 2002; 62(9): 2447 - 2454.
[Abstract] [Full Text] [PDF]

Home page